IP Library Granted Patent US 8,679,834
Granted Patent B2
US 8,679,834 · App. 13/382,426 · Granted Mar 25, 2014

Methods and compositions for use in cellular therapies

Inventors: Eleuterio Lombardo (Madrid, ES); Dirk Büscher (Madrid, ES)
Assignee: TiGenix S.A.U
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,679,834
App. No.
13/382,426
Granted
Mar 25, 2014
Kind
B2
Abstract

The present invention provides methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses thereof related to such methods.

Claims (9)

1. A method for treatment of immune-mediated inflammatory disorders, in a subject having one or more symptoms associated with said disorders, which comprises direct delivery to a lymphatic organ of said subject a therapeutically effective amount of a composition comprising mesenchymal stem cells.

2. The method according to claim 1 , wherein the composition is administered to a peripheral lymphatic organ.

3. The method of claim 2 wherein said peripheral lymphatic organ is a lymph node.

4. The method of claim 3 wherein said lymph node is an axillary or inguinal lymph node.

5. The method of claim 1 wherein said administration is carried out by means of a syringe.

6. The method of claim 5 , further comprising the step of using a radiological, ultrasound or imaging device to monitor the location of an injection needle.

7. The method of claim 1 , wherein the disorder is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

8. The method of claim 1 , wherein the mesenchymal stem cells are adipose-derived mesenchymal stem cells.

9. The method of claim 1 , wherein the mesenchymal stem cells are bone marrow mesenchymal stem cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: TIGENIX, S.A.U.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058320/0042 →
CHANGE OF NAME Recorded Aug 8, 2013
From: CELLERIX, S.A.
To: TIGENIX, S.A.U.
Reel/Frame 030987/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2012
From: LOMBARDO, ELEUTERIO; BUSCHER, DIRK
To: CELLERIX SA
Reel/Frame 028067/0678 →
Continuity (2)
Provisional Application 61224275 · Jul 9, 2009
Related Publication 20120308585A1 · Dec 6, 2012